09:23 AM EST, 12/10/2024 (MT Newswires) -- US stocks looked set to open relatively flat in Tuesday's trading session as investors awaited key inflation data set for release on Wednesday.

Dow Jones Industrial Average futures were off 0.22%, S&P 500 futures edged 0.02% higher, and Nasdaq futures gained 0.13%.

Oil prices were moving slightly lower, with front-month global benchmarks Brent crude and West Texas Intermediate crude declining 0.15% and 0.07% respectively.

In other world markets, Japan's Nikkei gained 0.53%, Hong Kong's Hang Seng was down 0.50%, and China's Shanghai Composite rose 0.59%. In Europe's early afternoon session, the UK's FTSE 100 was off 0.60%, while Germany's DAX edged 0.1% higher, and France's CAC was down 0.69%.

Among rising shares, Chimerix ( CMRX ) soared 171% after the biotech firm said late Monday it will submit a new drug application to the FDA before the end of the year for accelerated approval of dordaviprone to treat recurrent H3 K27M-mutant diffuse glioma. Cumberland Pharmaceuticals ( CPIX ) jumped 135% after it said Tuesday that the FDA approved a supplemental NDA for acetadote to prevent or lessen liver injury after ingesting potentially toxic amounts of acetaminophen. And shares of uniQure (QURE) shot up 95% after it said Tuesday that its reached an agreement with the FDA on elements of an Accelerated Approval pathway for its drug AMT-130 to treat Huntington's disease.

On the losing side, CervoMed ( CRVO ) plummeted 73% after it said Tuesday that topline data from a phase 2b clinical trial evaluating neflamapimod to treat patients with dementia with Lewy bodies failed to meet its primary and secondary endpoints. Biora Therapeutics ( BIOR ) plunged 45% after it said in a regulatory filing Tuesday that Nasdaq has determined to delist its securities for failing to comply with the market value of listed securities requirement. And MEDIROM Healthcare Technologies ( MRM ) shares tumbled 39% after it said late Monday that it has launched a public offering of 2,860,000 American Depositary Shares at $1.75 each for gross proceeds of approximately $5 million.